|
|
|
| home > white papers > Points to Consider When Developing a TMF (Trial Master File) Strategy - Phlexglobal Ltd |
|
|
 WHITE PAPERS |
|
Phlexglobal Ltd
|
|
Points to Consider When Developing a TMF (Trial Master File) Strategy
|
|
Many organizations are currently outsourcing clinical trial activities
to one or more contract research organizations (CROs). This strategy
enables companies to leverage specialized expertise and take advantage
of flexible resourcing throughout the conduct of a clinical trial.
Outsourcing minimizes the costs of recruiting experts, building a team
and maintaining an infrastructure. However, it can also add complexity
as the organization looks to meets its compliance obligations regarding
clinical trial documentation.
The documentation referred to in
Article 15(5) of Directive 2001/20/EC as the trial master file shall
consist of essential documents, which enable both the conduct of a
clinical trial and the quality of the data produced to be evaluated.1
This essential study specific documentation is also known as the TMF. As
organizations try to minimize their reliance on paper files, the
electronic TMF (eTMF) has emerged. A current industry initiative to
standardize the organization of this content is known as the TMF
Reference Model. This model is helping standardization efforts across
paper and electronic systems.
As companies implement outsourcing
strategies, CROs and sponsor organizations look for a common foundation
on which to build their TMF capabilities. The following paper outlines
some of the challenges organizations face when outsourcing clinical
trial activities to multiple contract research organizations and a
strategy to facilitate partnering and management of trial information
between sponsors and CROs.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
3P Biopharmaceuticals renews its “Credit Impôt Recherche” (CIR) by the French Ministry of Higher Education and Research
[Noáin, April 22, 2020] 3P Biopharmaceuticals, a European leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has successfully extended its French CIR certificate for another four-year period: 2020-2024.
More info >> |
|
 |
White Papers |
 |
|
Finding the Right End-to-End Safety Solution for Your Needs
Bioclinica
With upcoming changes, including the implementation of the International Conference on Harmonisation (ICH) E2B(R3) Electronic Transmission of Individual Case Safety Report and Identification of Medicinal Products (IDMP) standards, the current state of safety reporting can be confusing. Your existing safety system may not be flexible enough to accommodate these changing regulations, which are still moving targets regarding the details needed for a comprehensive solution with the right level of processes, company-to-company integrations and finalized regional rules.
More info >> |
|
 |
Industry Events |
 |
12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology
8-11 February 2021, Vienna, Austria
In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >> |
|
|
|
.jpg)
